Brian Eastman

449 total citations
12 papers, 253 citations indexed

About

Brian Eastman is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Brian Eastman has authored 12 papers receiving a total of 253 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brian Eastman's work include Cancer-related Molecular Pathways (3 papers), Cancer therapeutics and mechanisms (2 papers) and Advanced Breast Cancer Therapies (2 papers). Brian Eastman is often cited by papers focused on Cancer-related Molecular Pathways (3 papers), Cancer therapeutics and mechanisms (2 papers) and Advanced Breast Cancer Therapies (2 papers). Brian Eastman collaborates with scholars based in United States and United Kingdom. Brian Eastman's co-authors include Donald J. Skalitzky, Bernard T. Golding, Karen A. Maegley, Roger J. Griffin, Zdeněk Hostomský, Xiaohong Yu, Nicola J. Curtin, Stephen E. Webber, Joseph Marakovits and A. Hilary Calvert and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Brian Eastman

11 papers receiving 248 citations

Peers

Brian Eastman

ONCOL

CMN

Shuqun Lin United States

Kiran S. Toti United States

Dean A. Wacker United States

Ronald G. Almquist United States

Shyama Sidique United States

Alan S. Florjancic United States

Martin P. Allen United States

Jon J. Hangeland United States

Kenneth P. Spina United States

Helen J. Mason United Kingdom

Shuqun Lin United States

Brian Eastman

76 ×0.6

95 ×0.9

25 ×0.2

ONCOL

19 ×1.0

CMN

10 ×0.6

Citations per year, relative to Brian Eastman Brian Eastman (= 1×) peers Shuqun Lin

Countries citing papers authored by Brian Eastman

Since Specialization

Citations

This map shows the geographic impact of Brian Eastman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Eastman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Eastman more than expected).

Fields of papers citing papers by Brian Eastman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Eastman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Eastman. The network helps show where Brian Eastman may publish in the future.

Co-authorship network of co-authors of Brian Eastman

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Eastman. A scholar is included among the top collaborators of Brian Eastman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Eastman. Brian Eastman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

McMillan, Elizabeth A., Carine Bossard, Carsten Merkwirth, et al.. (2022). Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models. Cancer Research. 82(12_Supplement). 3928–3928.

Bossard, Carine, et al.. (2021). The Pan-Clk/Dyrk Inhibitor Cirtuvivint (SM08502) Exposes Mechanistic Underpinnings of Alternative Splicing As a Therapeutic Vulnerability in Heme Malignancies. Blood. 138(Supplement 1). 2950–2950. 1 indexed citations

Chung, Heekyung, et al.. (2020). Abstract 6401: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt and cyclin D-CDK4/6-RB pathway inhibition in hormone-receptor-positive (HR+) breast cancer models. Cancer Research. 80(16_Supplement). 6401–6401. 1 indexed citations

Bossard, Carine, Nathalia Cruz, Kevin Chiu, et al.. (2020). Abstract 5691: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models. Cancer Research. 80(16_Supplement). 5691–5691. 4 indexed citations

Bossard, Carine, et al.. (2019). Abstract A02: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models. Cancer Research. 79(24_Supplement). A02–A02. 1 indexed citations

Bossard, Carine, Igor Astsaturov, Nathalia Cruz, et al.. (2019). Abstract C09: Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models. Cancer Research. 79(24_Supplement). C09–C09. 1 indexed citations

Bossard, Carine, Kevin Chiu, Heekyung Chung, et al.. (2019). Effects of SM08502, a novel, oral small-molecule inhibitor of Wnt pathway signaling, on gene expression and antitumor activity in colorectal cancer (CRC) models.. Journal of Clinical Oncology. 37(15_suppl). e15185–e15185. 3 indexed citations

Poon, Steve F., Brian Eastman, Deborah F. Chapman, et al.. (2004). 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorganic & Medicinal Chemistry Letters. 14(22). 5477–5480. 19 indexed citations

White, Alex W., Nicola J. Curtin, Brian Eastman, et al.. (2004). Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(10). 2433–2437. 60 indexed citations

10.

Eastman, Brian, Chixu Chen, Nicholas D. Smith, et al.. (2004). Expedited SAR study of an mGluR5 antagonists: generation of a focused library using a solution-phase Suzuki coupling methodology. Bioorganic & Medicinal Chemistry Letters. 14(22). 5485–5488. 11 indexed citations

11.

Skalitzky, Donald J., Joseph Marakovits, Karen A. Maegley, et al.. (2002). Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors. Journal of Medicinal Chemistry. 46(2). 210–213. 126 indexed citations

12.

Johnson, Theodore, Hua Ye, Edward L. Brown, et al.. (2002). Structure-Based Design of a Parallel Synthetic Array Directed Toward the Discovery of Irreversible Inhibitors of Human Rhinovirus 3C Protease. Journal of Medicinal Chemistry. 45(10). 2016–2023. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact